BTIG Research Reaffirms “Buy” Rating for Sionna Therapeutics (NASDAQ:SION)

Sionna Therapeutics (NASDAQ:SION)‘s stock had its “buy” rating reiterated by research analysts at BTIG Research in a research report issued on Monday,Benzinga reports. They currently have a $58.00 target price on the stock. BTIG Research’s target price would suggest a potential upside of 70.14% from the company’s previous close.

A number of other research firms also recently weighed in on SION. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 29th. Raymond James Financial reiterated a “strong-buy” rating and set a $53.00 target price on shares of Sionna Therapeutics in a research report on Monday, January 5th. Citigroup assumed coverage on shares of Sionna Therapeutics in a research report on Tuesday, February 24th. They issued an “outperform” rating for the company. Citizens Jmp began coverage on shares of Sionna Therapeutics in a research note on Tuesday, February 24th. They set a “market outperform” rating and a $63.00 price target for the company. Finally, Lifesci Capital upgraded Sionna Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $50.57.

Sionna Therapeutics Price Performance

Shares of SION opened at $34.09 on Monday. The company has a market capitalization of $1.52 billion and a PE ratio of -17.48. Sionna Therapeutics has a one year low of $7.26 and a one year high of $45.00. The company’s fifty day moving average price is $39.42 and its 200 day moving average price is $35.31.

Sionna Therapeutics (NASDAQ:SION) last announced its earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.61) by $0.15.

Insider Activity

In other news, major shareholder Tpg Gp A, Llc sold 250,000 shares of the business’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $40.00, for a total value of $10,000,000.00. Following the transaction, the insider directly owned 6,494,962 shares of the company’s stock, valued at $259,798,480. The trade was a 3.71% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Orbimed Advisors Llc sold 33,356 shares of the firm’s stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $44.55, for a total value of $1,486,009.80. Following the sale, the director directly owned 3,561,655 shares of the company’s stock, valued at $158,671,730.25. This represents a 0.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 382,368 shares of company stock worth $15,898,607. Insiders own 3.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new stake in Sionna Therapeutics during the 4th quarter worth about $36,000. Russell Investments Group Ltd. acquired a new position in shares of Sionna Therapeutics during the third quarter worth approximately $30,000. Balyasny Asset Management L.P. bought a new stake in shares of Sionna Therapeutics during the fourth quarter valued at approximately $58,000. BNP Paribas Financial Markets bought a new stake in shares of Sionna Therapeutics during the second quarter valued at approximately $31,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Sionna Therapeutics in the fourth quarter valued at approximately $89,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.